Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue.

ABSTRACT: Glioblastoma (GBM) is the most lethal intracranial tumor. Sequencing technologies have supported personalized therapy for precise diagnosis and optimal treatment of GBM by revealing clinically actionable molecular characteristics. Although accumulating sequence data from brain tumors and matched normal tissues have facilitated a comprehensive understanding of genomic features of GBM, these in silico evaluations could gain more biological credibility when they are verified with in vitro and in vivo models. From this perspective, GBM cell lines with whole exome sequencing (WES) datasets of matched tumor tissues and normal blood are suitable biological platforms to not only investigate molecular markers of GBM but also validate the applicability of druggable targets. Here, we provide a comple

SUBMITTER: Kim SC 

PROVIDER: S-EPMC10338444 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature